Nathan Ihle
Senior VP, Pharmaceutical Operations at Bolt Biotherapeutics, Inc. - Redwood City, California, US
Nathan Ihle's Colleagues at Bolt Biotherapeutics, Inc.
Palani Balu
Principal Scientist - Leading Bioconjugation Process Development (PDM/CMC Group)
Nathan Ihle's Contact Details
(650) 665-9295
Redwood City,California,United States
Bolt Biotherapeutics, Inc.
Nathan Ihle's Company Details
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.